Evaluating Safety Profiles and Adherence Challenges in Wilson Disease Therapy

This episode, titled 'Evaluating Safety Profiles and Adherence Challenges in Wilson Disease Therapy,' features panelists discussing the distinct adverse event profiles of copper-clearing medications. Dr. Peter Hedera outlines the significant long-term risks associated with D-penicillamine, including bone marrow suppression, lupus-like syndromes, and "progeric" skin changes such as cutis laxa caused by impaired elastin cross-linking. These disfiguring skin changes and potential impacts on wound healing often make penicillamine less desirable for long-term use compared to trientine, which generally offers a more favorable safety profile with fewer systemic complications.

The conversation also addresses the practical hurdles of zinc therapy, such as gastric irritation and a persistent metallic aftertaste, which can lead to nausea and decreased compliance. The experts emphasize that adherence is not just a matter of frequency but also the stringent requirement to take these medications away from food. This is particularly challenging for adolescents and young adults who may find it difficult to coordinate multiple daily doses with their eating habits. The panel concludes by noting that advancements in twice-daily or even once-daily dosing schedules, particularly for trientine formulations, represent a major step forward in reducing the daily burden of disease management.

In the next episode, 'Monitoring Treatment Response and Preventing Copper Insufficiency in Wilson Disease,' panelists will continue their discussion on Wilson disease and highlight the rigorous laboratory and clinical protocols required to ensure therapeutic success. The experts discuss the cadence of monitoring—from acute induction to long-term maintenance—and the biomarkers used to balance effective copper removal with the risks of over-treatment.